F. Hoffmann-La Roche Ltd - Company Profile
Powered by 
All the sales intelligence you need on F. Hoffmann-La Roche Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how F. Hoffmann-La Roche Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with F. Hoffmann-La Roche Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
F. Hoffmann-La Roche Ltd (Roche), a subsidiary of Roche Holding AG, is a biotechnology company and a provider of in-vitro diagnostics as well as a supplier of transformative innovative solutions across major disease areas. It provides drugs for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in-vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Roche is headquartered in Basel, Basel-Stadt, Switzerland.
Headquarters
Switzerland
Address
Grenzacherstrasse 124, Basel, Basel-Stadt, 4070
Website
www.roche.com
Telephone
41 61 6881111
Industry
Pharmaceuticals and Healthcare
F. Hoffmann-La Roche Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cardiometabolic Diseases | Accutane |
| Diabetes | Actemra |
| Haematology | Alecensa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In September, the company received approval from the U.S. Food and Drug Administration for Enspryng (satralizumab) to treat adult and adolescent patients with myelin oligodendrocyte glycoprotein antibody-associated disease. |
| 2026 | Regulatory Approval | In September, the company received approval from the European Commission for Susvimo (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration. |
| 2026 | Regulatory Approval | In September, the company seeks approval from the European Commission for Ocrevus (ocrelizumab) intravenous infusion for the treatment of paediatric patients with relapsing forms of multiple sclerosis. |
Competitor Comparison
| Key Parameters | F. Hoffmann-La Roche Ltd | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | United States of America | United States of America |
| City | Basel | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Basel-Stadt | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | - | 138,200 | 50,000 | 75,000 | 75,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Severin Schwan | Chairman | Executive Board | 2023 | 59 |
| Thomas Schinecker | Chief Executive Officer | Senior Management | 2023 | 51 |
| Alan Hippe | Chief Financial Officer | Senior Management | 2011 | 59 |
| Wafaa Mamilli | Chief Technology Officer; Chief Digital Officer | Senior Management | 2025 | 59 |
| Cristina A. Wilbur | Chief People Officer | Senior Management | 2016 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer